Advaxis (Advaxis) ROCE % : -272.94% (As of Mar. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Advaxis ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Advaxis's annualized ROCE % for the quarter that ended in Mar. 2023 was -272.94%.

Advaxis ROCE % Historical Data

The historical data trend for Advaxis's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis ROCE % Chart

Advaxis Annual Data

Trend

Oct13

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

ROCE %

Get a 7-Day Free Trial

-125.48

-44.86

-69.63

-50.68

-52.00

Advaxis Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Mar23
ROCE %	Get a 7-Day Free Trial															-40.78	-30.82	-54.13	-74.18	-272.94

Advaxis ROCE % Calculation

Advaxis's annualized ROCE % for the fiscal year that ended in Oct. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2022 )		(A: Oct. 2021 )		(A: Oct. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2022 )		(A: Oct. 2021 )		(A: Oct. 2022 )
	=	-16.257	/	( ( (46.78 - 7.88)	+	(25.93 - 2.303) )	/ 2 )
	=	-16.257	/	( (38.9	+	23.627)	/ 2 )
	=	-16.257	/	31.2635
	=	-52.00 %

Advaxis's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2023 )		(Q: Oct. 2022 )		(Q: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2023 )		(Q: Oct. 2022 )		(Q: Mar. 2023 )
	=	-47.476	/	( ( (25.93 - 2.303)	+	(20.995 - 9.833) )	/ 2 )
	=	-47.476	/	( ( 23.627	+	11.162 )	/ 2 )
	=	-47.476	/	17.3945
	=	-272.94 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

Advaxis (OTCPK:ADXS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Advaxis ROCE % Related Terms

Thank you for viewing the detailed overview of Advaxis's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Advaxis (Advaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540

Website

https://www.advaxis.com

Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.

Executives

Roy Golan	officer: Chief Financial Officer	24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly	director	C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach	director	C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell	director	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg	director	2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib	director	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel	10 percent owner	YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman	officer: Chief Accounting Officer	201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070